



WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Last updated 15-July-2020 (data as of 12-October-2020)
Next overall update End 2020



Select a country

Nigeria

| | | | | | |
|----------------------------|------------|-----------------------------|--------------------|---|------------------|
| Development status: | Developing | GNI / capita (US\$): | 2'030 ¹ | Infant (under 12 months) mortality rate: | 65 ² |
| | | GDP / capita (US\$): | 5'348 ¹ | Child (under 5 years) mortality rate: | 100 ² |

Population data in thousands³

| | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1990 | 1980 |
|-------------------------|---------|---------|---------|---------|---------|---------|--------|--------|
| Total population | 200'964 | 195'875 | 190'873 | 185'960 | 181'137 | 122'284 | 95'212 | 73'424 |
| Births | 7'535 | 7'433 | 7'334 | 7'236 | 7'137 | 5'288 | 4'217 | 3'439 |
| Surviving infants | 7'086 | 6'977 | 6'869 | 6'761 | 6'651 | 4'697 | 3'683 | 2'997 |
| Pop. less than 5 years | 33'409 | 32'917 | 32'412 | 31'831 | 31'132 | 21'074 | 16'799 | 13'367 |
| Pop. less than 15 years | 87'796 | 85'924 | 84'009 | 82'020 | 79'937 | 53'321 | 42'821 | 32'353 |
| Female 15-49 years | 46'238 | 44'930 | 43'672 | 42'479 | 41'363 | 28'084 | 21'183 | 16'567 |

Number of reported cases

[\(Click for retrospective incidence data for Nigeria\)](#)

| | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1990 | 1980 |
|-----------------------|--------|-------|--------|--------|--------|---------|---------|---------|
| Diphtheria | 2'289 | 1'870 | 0 | — | — | 3'995 | 1'768 | 165 |
| Japanese encephalitis | — | — | — | — | — | — | — | — |
| Measles*** | 28'094 | 7'063 | 11'190 | 17'136 | 12'423 | 212'183 | 115'682 | 162'106 |
| Mumps | — | — | — | — | — | — | — | — |
| Pertussis | — | 7'897 | 4'244 | — | 6'592 | 38'910 | 42'929 | 48'996 |
| Polio* | 18 | 34 | 0 | 5 | 1 | 638 | 1'873 | 816 |
| Rubella*** | 1'644 | 4'772 | 543 | 503 | 419 | — | — | — |
| Rubella (CRS) | — | — | — | — | — | — | — | — |
| Tetanus (neonatal) | 137 | 130 | 187 | 34 | 53 | 1'643 | 1'060 | — |
| Tetanus (total)** | 138 | 131 | 187 | 34 | 53 | 1'643 | 2'703 | 3'095 |
| Yellow fever | 154 | 47 | 26 | 0 | 0 | 0 | 4'075 | 8 |

* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: <https://extranet.who.int/polis/public/CaseCount.aspx> it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP].

** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

*** For 2019, if a country did not submit a joint reporting form, measles and rubella cases were sourced from data reported through the monthly surveillance data available from:

https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition

Most recent coverage survey⁴

Official country estimates⁵

[\(Click for retrospective coverage estimates data for Nigeria\)](#)

| Vaccine | year | result | method | % card seen | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1990 | 1980 |
|---------|------|--------|--------|-------------|------|------|------|------|------|------|------|------|
| BCG | 2017 | 67 | DHS | 40 | 67 | 75 | 53 | 58 | 58 | 34 | 80 | — |
| DTP1 | 2017 | 65 | DHS | 40 | 65 | 72 | 49 | 55 | 55 | 48 | — | — |
| DTP3 | 2017 | 50 | DHS | 40 | 57 | 58 | 33 | 45 | 45 | 38 | 56 | — |
| IPV1 | — | — | — | — | 53 | 93 | 99* | 45 | 45 | — | — | — |
| HepB_BD | — | — | — | — | 52 | 63 | 30 | 36 | 35 | — | — | — |
| HepB3 | 2017 | 50 | DHS | 40 | 57 | 58 | 33 | 45 | 45 | — | — | — |
| Hib3 | 2017 | 50 | DHS | 40 | 57 | 58 | 33 | — | — | — | — | — |
| JapEnc | — | — | — | — | — | — | — | — | — | — | — | — |
| MCV1 | — | — | — | — | 54 | 63 | 42 | 43 | 43 | 30 | 48 | — |
| MCV2 | — | — | — | — | 9 | — | — | — | — | — | — | — |
| MenA | — | — | — | — | 22 | — | — | — | — | — | — | — |
| PCV1 | — | — | — | — | 62 | 72 | 99* | 44 | 44 | — | — | — |
| PCV2 | — | — | — | — | 54 | 64 | 95 | 35 | 35 | — | — | — |
| PCV3 | 2017 | 47 | DHS | 40 | 57 | 58 | 99* | 29 | 29 | — | — | — |
| Pol3 | 2017 | 47 | DHS | 40 | 57 | 58 | 33 | 37 | 37 | 38 | 55 | — |
| Rota1 | — | — | — | — | — | — | — | — | — | — | — | — |
| RotaC | — | — | — | — | — | — | — | — | — | — | — | — |
| RCV1 | — | — | — | — | — | — | — | — | — | — | — | — |
| TT2plus | 2017 | 53 | DHS | 40 | 40 | 62 | 60 | 47 | 40 | — | 56 | — |
| PAB | — | — | — | — | — | — | — | — | — | 48 | — | — |
| VAD1 | — | — | — | — | — | 19 | 13 | 6 | 16 | — | — | — |
| YFV | 2015 | 39 | MICS | 29 | 80 | 61 | 39 | 41 | 41 | — | — | — |

* indicates the country reported above 100% coverage.

Next update: Mid July 2021

WHO-UNICEF estimates⁶

[\(Click for full retrospective WHO-UNICEF coverage estimates data for Nigeria\)](#)


| Vaccine | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1990 | 1980 |
|---------|------|------|------|------|------|------|------|------|
| BCG | 67 | 67 | 67 | 64 | 53 | 44 | 80 | — |
| DTP1 | 65 | 65 | 65 | 62 | 49 | 42 | 79 | — |
| DTP3 | 57 | 56 | 55 | 53 | 42 | 29 | 56 | — |
| HepB3 | 57 | 56 | 55 | 53 | 42 | — | — | — |
| HepB_BD | — | — | — | — | — | — | — | — |
| Hib3 | 57 | 56 | 55 | 53 | 42 | — | — | — |
| IPV1 | 53 | 53 | 53 | 52 | 42 | — | — | — |
| MCV1 | 54 | 54 | 54 | 51 | 42 | 33 | 54 | — |
| MCV2 | 9 | — | — | — | — | — | — | — |
| PCV3 | 57 | 55 | 53 | 49 | 36 | — | — | — |
| Pol3 | 57 | 56 | 55 | 53 | 42 | 31 | 55 | — |
| RCV1 | — | — | — | — | — | — | — | — |
| RotaC | — | — | — | — | — | — | — | — |

| | | | | | | | | | |
|-----|---|----|----|----|----|----|---|---|---|
| YFV |  | 54 | 54 | 54 | 51 | 42 | - | - | - |
|-----|---|----|----|----|----|----|---|---|---|

[Click to download WHO-UNICEF coverage estimates data for PAB time series.](#)

[Click to download WHO-UNICEF coverage estimates data for HPV time series.](#)

| | | | | |
|---|-----|--|---------------------------|----|
| Number of districts in the country | 774 | Proportion of districts reporting DTP3 coverage: | / Greater or equal to 90% | 46 |
| | | | From 80 to 89% | 14 |
| | | | From 50 to 79% | 31 |
| | | | \ Less than 50% | 9 |
| % of coverage reports received at national level vs number of reports expected | 99 | Proportion of districts not reporting DTP3 coverage | | 0 |



Immunization Schedule (2019 or latest available)

Hovering over an antigen reveals its fuller definition

| Vaccine | Schedule | Entire country | Comment |
|----------------|---|----------------|--|
| BCG | birth; | Yes | |
| DTwPHibHepB | 6, 10, 14 weeks; | Yes | |
| HepB_Pediatric | birth; | Yes | |
| HPV | | Yes | Planned introduction in 2021/2022; females, 9-13 year old |
| IPV | 14 weeks; | Yes | |
| Measles | 9, 15 months; | Yes | 2nd dose introduced in southern states; planned introduction in northern states in Q4 2020 |
| MenA_conj | 9 months; | Yes | from August 2019 |
| OPV | birth; 6, 10, 14 weeks; | Yes | |
| Pneumo_conj | 6, 10, 14 weeks; | Yes | |
| Rotavirus | 6, 10, 14 weeks; | Yes | Planned introduction in October 2020 and 2021 in phased approach |
| Td | 1st contact; +1, +6 months; +1, +1 years; | Yes | pregnant women |
| VitaminA | 6, 12 months; | Yes | 6-23 months |
| YF | 9 months; | Yes | |

Immunization indicators

| Indicator | Expected answer | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Planning and management | | | | | | | | |
| Has the country a Multi-Year Plan (MYP) for immunization? | Yes/No/NR | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| What years does the MYP cover? | number | 2018-2028 | 2016-2020 | 2016-2020 | 2016-2020 | 2011-2015 | 2011-2015 | 2011-2015 |
| System performance | | | | | | | | |
| Total N° districts in country | number | 774 | 774 | 774 | 774 | 774 | 774 | 774 |
| N° districts with DTP3 coverage >=80% | number | 579 | 684 | 537 | 616 | 616 | 554 | 117 |
| % of districts with DTP3 coverage >=80% | From 0 to 100% | 75 | 88 | 69 | 80 | 80 | 72 | 15 |
| N° districts with measles (MCV1) coverage >=95% | number | 283 | 457 | 430 | 402 | 409 | 393 | 192 |
| % of districts with MCV1 coverage >=95% | From 0 to 100% | 37 | 59 | 56 | 52 | 53 | 51 | 25 |
| Safety | | | | | | | | |
| Has the country a vaccine adverse events review committee? | Yes/No/NR/ND | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Is there a national system to monitor adverse events following immunization (AEFI)? | Yes/No/NR | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Finance | | | | | | | | |
| % of Immunization expenditure financed, using Government funds? | From 0 to 100% | 26 | 24 | 29 | 40 | 24 | | |
| National Immunization Advisory Mechanism | | | | | | | | |
| Has the country a standing technical advisory group on immunization (NITAG)? | Yes/No/NR | Yes | Yes | Yes | Yes | No | No | Yes |

Sources

- 1 "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
- 2 UN Inter-agency Group for Child Mortality Estimation (<https://childmortality.org/data>)
- 3 "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
- 4 UNICEF/WHO survey database
- 5 If no official estimate is available, the administrative coverage is reported. "" indicates coverage over 99.5%.
- 6 WHO-UNICEF estimates.